URGN Stock Cash Flow Statements

UroGen Pharma Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

UroGen Pharma Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31

cash flows from operating activities
net income	-49,940,000	-43,843,000	-37,512,000	-23,673,000	-33,403,000	-32,286,000	-26,016,000	-21,879,000	-24,136,000	-30,213,000	-28,869,000	-25,831,000	-26,691,000	-28,392,000	-28,452,000	-30,211,000	-26,222,000	-25,935,000	-30,526,000	-28,816,000	-31,349,000	-37,793,000	-38,973,000	-22,252,000	-22,477,000	-21,444,000
adjustment to reconcile net income to net cash from operating activities:
depreciation and amortization	80,000	72,000	68,000	68,000	70,000	123,000	190,000	186,000	209,000	217,000	236,000	239,000	234,000	215,000	213,000	217,000	210,000	191,000	121,000	117,000	96,000	82,000	108,000	65,000	60,000	63,000
accrued financing on prepaid forward obligation	2,012,000	-1,889,000	6,064,000	3,074,000	3,340,000	2,599,000	2,790,000	2,732,000	3,109,000	2,873,000	2,988,000	2,660,000	4,070,000	4,289,000	6,265,000	6,253,000
accretion on marketable securities	-866,000	-774,000
share-based compensation	2,733,000	3,069,000	3,303,000	3,489,000	3,560,000	2,756,000	2,611,000	2,224,000	2,222,000	2,286,000	2,368,000	2,440,000	2,823,000	2,949,000	5,357,000
amortization (accretion) of discount on long-term debt	400,000	374,000
amortization of right of use assets	516,000	425,000		198,000	193,000	228,000		229,000	222,000	218,000	214,000	196,000
acquisitions of ipr&d	0	3,128,000
changes in operating assets and liabilities:
inventory	462,000	1,637,000	-1,633,000	-152,000	-199,000	-1,570,000	-671,000	-14,000	477,000	-1,140,000	283,000	-165,000	-556,000	76,000	-1,024,000	-387,000	-90,000	-1,367,000	-618,000
accounts receivable	-11,000	664,000	2,500,000	-5,387,000	-3,257,000	1,285,000	-2,596,000	2,658,000	-3,012,000	211,000	-3,275,000	2,166,000	-2,096,000	2,218,000	-3,934,000	1,728,000	-3,211,000	746,000	-4,237,000
prepaid expenses and other current assets	928,000	-4,138,000	5,208,000	-1,845,000	-1,717,000	-210,000	5,757,000	-3,315,000	-577,000	-1,045,000	-522,000	-146,000						-2,952,000	931,000
other non-current assets	-430,000	218,000	-219,000	303,000	425,000	940,000	12,000	767,000	344,000	-421,000	-269,000	-556,000	-275,000	-169,000	553,000	-547,000
accounts payable and accrued expenses	640,000	2,891,000	7,746,000	-4,069,000	5,596,000	1,620,000	2,455,000	-2,320,000	-727,000	4,747,000	3,027,000	708,000						535,000	1,261,000
employee related accrued expenses	4,679,000	-3,603,000	1,541,000	2,180,000	1,864,000	-5,829,000	2,662,000	1,431,000	1,802,000	-3,338,000	1,632,000	197,000						-4,842,000	1,763,000
other current liabilities	-421,000	483,000									1,000	0	-1,005,000	301,000	642,000	-790,000
lease liabilities	-606,000	-738,000	-408,000	-184,000	-195,000	-247,000	-221,000	-262,000	-252,000	-252,000	-269,000	-282,000
restricted deposit			-1,000	0
net cash from operating activities	-39,825,000	-42,024,000	-13,619,000	-27,664,000	-23,748,000	-31,735,000	-12,996,000	-17,299,000	-20,274,000	-25,807,000	-21,752,000	-17,612,000	-24,199,000	-23,996,000	-20,070,000	-18,476,000	-18,945,000	-27,401,000	-21,242,000	-25,080,000	-23,929,000	-35,635,000	-26,000,000	-12,528,000	-14,555,000	-17,934,000
capex	-141,000	-44,000	-115,000	-96,000	0	0	-56,000	-100,000	-15,000	-23,000	-13,000	-153,000	-63,000	-25,000	-202,000	-194,000	-69,000	-287,000	0	-660,000	-287,000	-96,000	0	-49,000	0	-44,000
free cash flows	-39,966,000	-42,068,000	-13,734,000	-27,760,000	-23,748,000	-31,735,000	-13,052,000	-17,399,000	-20,289,000	-25,830,000	-21,765,000	-17,765,000	-24,262,000	-24,021,000	-20,272,000	-18,670,000	-19,014,000	-27,688,000	-21,242,000	-25,740,000	-24,216,000	-35,731,000	-26,000,000	-12,577,000	-14,555,000	-17,978,000
cash flows from investing activities
purchases of marketable securities	-1,789,000	-66,351,000	-9,229,000				-14,823,000	-10,833,000	0	-24,176,000	0					-9,939,000
maturities of marketable securities	30,336,000	40,432,000	69,965,000	12,140,000	12,082,000	13,518,000	3,535,000	11,334,000	3,735,000	30,469,000	23,121,000	27,669,000	-88,000	13,621,000	9,631,000	18,330,000	10,984,000	15,311,000	49,638,000	13,893,000	38,111,000	22,499,000	38,490,000
purchases of property and equipment	-141,000	-44,000	-115,000	-96,000			-56,000	-100,000	-15,000	-23,000	-13,000	-153,000	-63,000	-25,000	-202,000	-194,000	-69,000	-287,000		-660,000	-287,000	-96,000		-49,000
net cash from investing activities	28,406,000	-25,963,000	60,621,000	-106,750,000	11,998,000	13,518,000	-11,344,000	401,000	3,720,000	6,270,000	23,108,000	-35,493,000	-151,000	13,596,000	9,125,000	10,660,000	-30,740,000	15,024,000	49,465,000	13,234,000	17,514,000	13,025,000	9,296,000	-12,659,000	-142,186,000	-44,000
cash flows from financing activities
proceeds from exercise of options into ordinary shares	297,000	30,000	71,000	115,000			40,000	19,000	143,000	671,000	378,000	1,117,000			0	3,000	54,000	4,000	89,000	148,000	210,000	293,000	321,000	1,126,000	685,000	1,532,000
proceeds from pre-funded warrant issuance, net of issuance costs			0	0
proceeds from ordinary shares issuances, net of issuance costs
net cash from financing activities	296,000	34,000	71,000	39,606,000	100,285,000	54,657,000	40,000	116,077,000	143,000	671,000	25,368,000	1,101,000	-77,000	70,742,000	-32,000	-168,000	72,515,000	4,000	78,000	61,000	16,298,000	90,000	245,000	1,126,000	373,000	163,506,000
increase in cash and cash equivalents	-11,123,000	-67,953,000	47,073,000	-94,808,000	88,535,000	36,440,000	-24,300,000	99,179,000	-16,411,000	-18,866,000	26,724,000	-52,004,000	-24,427,000	60,342,000	-10,977,000	-7,984,000					9,883,000	-22,520,000	-16,459,000	-24,061,000	-156,368,000	145,528,000
cash, cash equivalents and restricted cash at beginning of period	0	173,062,000		0	0	95,822,000		0	0	56,220,000		1,000	-1,000	45,587,000		0	0	54,090,000
cash, cash equivalents and restricted cash at end of period	-11,123,000	105,109,000		-94,808,000	88,535,000	132,262,000		99,179,000	-16,411,000	37,354,000		-52,003,000	-24,428,000	105,929,000		-7,984,000	22,830,000	41,717,000
supplemental disclosures of non-cash activities
right of use assets obtained in exchange for new operating lease liabilities	1,313,000	2,045,000						27,000	0	95,000	0
proceeds from ordinary shares issuance, net of issuance costs		4,000	0
amortization of right-of-use assets
uncertain tax positions
proceeds from issuance of long-term debt, net of issuance costs
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
right-of-use assets obtained in exchange for new operating lease liabilities
(accretion) on marketable securities				-1,074,000	-298,000	-183,000	-412,000
amortization of discount on long-term debt				-592,000	223,000	-961,000		222,000	355,000	404,000	677,000
proceeds from issuance of long-term debt											24,990,000	0	-38,000	70,831,000
proceeds from ordinary share issuance, net of issuance costs					81,509,000	54,657,000
inventory obsolescence											255,000	350,000
proceeds from pre-funded warrant issuance, net of 1,654 of issuance costs							0
proceeds from ordinary share issuance, net of 2,288 of issuance costs							0
issuance cost related to at-the-market issuances											0	-16,000	-55,000	-89,000	-17,000	-116,000			-11,000
amortization (accretion) on marketable securities									-310,000	-354,000	-405,000
non-cash issuance cost														3,000												312,000
sales of marketable securities															0
proceeds from prepaid forward arrangement															-15,000	-55,000
amortization on marketable securities													119,000	50,000	133,000	162,000	-10,000	191,000
interest expense on long-term debt													121,000	282,000
non-cash new lease liabilities													1,413,000	6,000		0	-16,000	-20,000		22,000	-43,000	72,000
amortization of right of use asset														241,000	238,000	235,000	232,000	237,000	494,000	381,000	379,000	374,000
lease liability														-286,000		-262,000	-252,000	-400,000	-384,000	-409,000	-387,000	-361,000		-246,000	-201,000	-173,000
prepaid expense and other current assets														-1,800,000	-1,362,000	-805,000
accounts payable and accrued expense														-2,169,000	966,000	713,000
employee related accrued expense														-1,801,000	472,000	-297,000
purchase of marketable securities																			-1,000	1,000	-20,310,000	-9,378,000	-28,834,000
issuances of ordinary shares, net of issuance expenses
purchase of property and equipment																										-44,000
accrued issuance cost
new lease liabilities
issuances of ordinary shares, net of issuance expense
exercise of options																									-513,000	515,000
stock-based compensation																	6,046,000	6,195,000	6,526,000	6,763,000	7,119,000	7,617,000	8,065,000	7,243,000	7,212,000	7,447,000
non-cash purchases of property and equipment
decrease in cash and cash equivalents																		-12,373,000	28,301,000
current tax payable
change in restricted deposit																							-168,000	0
issuance of ordinary shares, net of issuance expenses																			0	-32,000			0	0
issuance cost
cash flows from operating activities:
amortization/accretion on marketable securities																				152,000	136,000	98,000	-75,000	-330,000
cash flows from investing activities:
cash flows from financing activities:
cash, cash equivalents and restricted cash at beginning of the period																				0	0	50,211,000
cash, cash equivalents and restricted cash at end of the period																				-11,785,000	9,883,000	27,691,000
supplemental disclosures of non-cash activities:
increase in inventory
increase in accounts receivable
increase in prepaid expenses and other current assets																					-517,000	-518,000	126,000	562,000	-1,041,000	-41,000
decrease in accounts payable and accrued expenses																					452,000	-2,498,000				-2,440,000
decrease in employee related accrued expenses																					1,669,000	-2,636,000				-1,591,000
supplemental disclosures of non-cash investing and financing activities:
non-cash purchase of property and equipment
issuance cost for shelf filing																						-203,000
fair value adjustment of warrants for preferred shares
realized loss on sale of short-term investment
change in lease liability
decrease (increase) in inventory
decrease in accounts receivable
increase in accounts payable and accrued expenses																							3,118,000	809,000
increase in deferred revenues
increase in employee related accrued expenses																							1,629,000	1,376,000
sale of short-term investments
proceeds from exercise of warrants for preferred shares
issuance cost for secondary offering
cash, cash equivalents and restricted cash at beginning of the year																							0	0
cash, cash equivalents and restricted cash at end of the year																							-16,459,000	-24,061,000	-156,368,000	247,099,000
exercise of warrants to preferred shares
exchange rate differences
right of use asset																								245,000	246,000	245,000
decrease in inventory
decrease in deferred revenues
sale of short-term investment
short-term investments
issuance of ordinary shares, net of issurance expenses																										161,974,000
cash, cash equivalents and restriced cash at beginning of the year																										101,571,000
decrease (increase) in accounts receivable
decrease (increase) in prepaid expenses and other current assets
payment of deferred equity offering cost
adjustments required to reconcile net income to net cash from operating activities:
depreciation
in process r&d
share based compensation
exchange rates differences
changes in operating asset and liabilities:
proceeds from issuance of preferred shares from 2014 share purchase agreement net of issuance cost
balance of cash and cash equivalents at beginning of the year
balance of cash and cash equivalents at end of the year
purchase of ip r&d in consideration for preferred a shares
non cash issuance cost

We provide you with 20 years of cash flow statements for UroGen Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of UroGen Pharma stock. Explore the full financial landscape of UroGen Pharma stock with our expertly curated income statements.

The information provided in this report about UroGen Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.